Longeveron (LGVN) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
Chair welcomed shareholders to the third annual meeting, emphasizing virtual participation and support.
Stockholders were informed about the process for submitting questions and the meeting's adherence to company bylaws.
Executive officers and independent auditors were introduced, with auditors available for questions.
Board and executive committee updates
Four Class III director nominees were presented for election to serve three-year terms expiring in 2027.
No additional nominations were received before the deadline, closing the nominations.
Shareholder proposals
Proposal to elect four directors for three-year terms.
Proposal to amend the 2021 Incentive Award Plan to increase shares available for issuance.
Proposal to ratify Marcum LLP as independent auditors for the fiscal year ending December 31, 2024.
Latest events from Longeveron
- ELPIS II topline data are anticipated in Q3 2026 as laromestrocel advances across four indications.LGVN
Investor presentation - ELPIS I showed 100% five-year transplant-free survival in treated HLHS patients.LGVN
Investor presentation - Laromestrocel advances across three indications, with pivotal trials planned or underway.LGVN
Investor presentation - Pivotal HLHS and planned Alzheimer's and PDCM trials anchor laromestrocel's pipeline.LGVN
Investor presentation - Laromestrocel spans three indications, with ELPIS II pivotal if positive.LGVN
Investor presentation - Lomecel-B advances across three indications, with encouraging HLHS, AD and frailty data.LGVN
Investor presentation - Laromestrocel's late-stage data and PRV eligibility position it for major value inflection.LGVN
Investor presentation - Q2 2026 net loss rose to $6.1M as cash runway extends into Q4 2026 ahead of key trial results.LGVN
Q2 2026 - All proposals, including director elections and share amendments, were approved by majority vote.LGVN
AGM 2026